Can J&J’s Rybrevant/Lazcluze Combo Stand Up To Tagrisso?
Executive Summary
The US FDA approved the J&J combination for certain first-line NSCLC patients, but there are concerns about safety. The company hopes a subcutaneous version of Rybrevant can address them.